In a patient with a known well‑differentiated neuroendocrine tumor who underwent microwave ablation of hepatic lesions, are heterogeneous, peripherally enhancing lesions in hepatic segments VII and V on a scan performed two months later consistent with expected post‑ablation changes or indicative of residual/metastatic disease?

Heterogeneous, Peripherally Enhancing Lesions Two Months Post-Ablation Are Highly Suspicious for Residual or Metastatic Neuroendocrine Disease, Not Expected Post-Ablation Changes

These imaging findings are concerning for treatment failure or new metastatic disease and warrant immediate further evaluation with biopsy or additional imaging, as peripheral enhancement with heterogeneity is a hallmark of viable neuroendocrine tumor metastases, not successful ablation.

Understanding the Imaging Pattern

The scan describes heterogeneous, peripherally enhancing lesions in hepatic segments VII and V. This enhancement pattern is critical to interpret correctly:

• Peripheral ring enhancement has a 98% positive predictive value for malignancy in the context of metastatic disease 1
• This pattern reflects enhancement in compact tumor cells located at the periphery of metastases 1
• Neuroendocrine tumor metastases characteristically show arterial hyperenhancement in the majority of cases, though they can behave variably 1

Expected Post-Ablation Appearance vs. Viable Tumor

What you should see after successful microwave ablation:

• A well-defined ablation zone without internal enhancement
• Possible thin, smooth peripheral rim enhancement representing benign inflammatory response (not heterogeneous or nodular)
• Progressive decrease in size over time
• No internal heterogeneity

What indicates treatment failure or residual disease:

• Heterogeneous internal enhancement (as described in this scan)
• Nodular or irregular peripheral enhancement
• Increasing size of lesions
• New arterial phase hyperenhancement within or adjacent to the ablation zone

The ACR guidelines specifically note that noncontrast images may be helpful in post-ablation assessment "in which it can be difficult to determine if a lesion is a viable tumor" 1, acknowledging this diagnostic challenge.

Clinical Context: Well-Differentiated Neuroendocrine Tumors

Your patient has a well-differentiated neuroendocrine tumor, which has specific imaging characteristics:

• These tumors typically show arterial hyperenhancement due to their hypervascular nature 1
• Multiphase imaging (arterial and portal venous phases) is essential for detection, as up to 59% may be isodense on single-phase imaging 1
• The heterogeneous appearance with peripheral enhancement strongly suggests viable tumor tissue rather than post-treatment change

Recommended Action Algorithm

Immediate next steps (within 2-4 weeks):

1. Obtain multiphase contrast-enhanced MRI with hepatocyte-specific contrast agent (gadoxetic acid) or dedicated multiphase CT if MRI contraindicated

   • This provides superior characterization compared to single-phase imaging
   • Arterial phase is critical for neuroendocrine metastases 1

2. Consider image-guided biopsy of the most suspicious lesion

   • Particularly important given the 2-month post-ablation timeframe
   • Histologic confirmation guides subsequent management decisions

3. Measure chromogranin A and other relevant neuroendocrine markers if not recently done

   • Rising markers support active disease

Treatment Implications Based on Findings

If residual/progressive disease is confirmed:

• Re-ablation may be considered for oligoprogressive disease, as thermal ablation (RFA/MWA) has demonstrated ability to control hepatic oligoprogression and prolong progression-free survival in well-differentiated NETs 2
• One study showed median PFS of 62.6 weeks per ablation procedure, with ability to delay systemic therapy change up to 123 weeks 2
• Systemic therapy escalation per ESMO guidelines, considering proliferative activity (Ki-67), SSTR expression, and tumor growth rate 3

Critical Pitfalls to Avoid

Do not assume these are benign post-ablation changes:

• The heterogeneous, peripherally enhancing pattern is atypical for uncomplicated post-ablation appearance
• Two months is sufficient time for the ablation zone to have stabilized
• The radiologist's interpretation ("suspicious for hepatic metastases") should be taken seriously given the high PPV of this enhancement pattern

Do not delay follow-up imaging or biopsy:

• Well-differentiated NETs can progress despite initial local therapy
• Early detection of treatment failure allows for timely intervention
• The presence of multiple lesions suggests either incomplete initial ablation or new metastatic disease

Ensure proper imaging technique for follow-up:

• Multiphase imaging is mandatory for neuroendocrine tumors 1
• Single-phase imaging will miss a significant proportion of lesions

This scan is not consistent with expected post-ablation changes and requires urgent further evaluation to determine if these represent residual viable tumor, new metastases, or the rare possibility of atypical post-ablation inflammation. The imaging characteristics strongly favor active disease.